Navigation Links
Cempra, Inc. Reports First Quarter 2013 Financial and Operating Results
Date:4/25/2013

mpra.com, and will be archived there for 30 days following the call. Please visit Cempra's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Cempra, Inc.Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are in advanced clinical development; solithromycin in Phase 3 for CABP and TAKSTA™ (CEM-102) in Phase 2 for prosthetic joint infections. Both seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others:  the costs, timing, regulatory review and results of our studies and clinical trials; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; our ability to obtain FDA approval of our product candidates; our dependence on the success of solithromycin and Taksta; our anticipated capital expenditures and our estimates regarding our capital requirements; the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties; the unpredictability of the size of the markets fo
'/>"/>

SOURCE Cempra, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cempra, Inc. to Present at 12th Annual Needham Healthcare Conference
2. Cempra, Inc. to Report First Quarter 2013 Financial and Operating Results, and Host Conference Call and Webcast on April 25, 2013
3. Cempra, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference
4. Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast on February 28, 2013
5. Cempra, Inc. to Present at Oppenheimer 23rd Annual Healthcare Conference
6. Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London
7. Cempra, Inc. to Report Third Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on November 8, 2012
8. Cempra, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference
9. Cempra, Inc. Reports Second Quarter 2012 Financial and Operating Results
10. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
11. Cempra, Inc. to Report Second Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on August 8, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... DALLAS , September 22, 2014 ... report "Cell Line Development Market by Product (Equipment, Media ... (Bioproduction, Tissue Engineering & Regenerative medicine, Toxicity Testing, ... to 2019", published by MarketsandMarkets, analyzes and studies ... Browse 114 market data tables ...
(Date:9/22/2014)... 2014 CytRx Corporation (Nasdaq: CYTR ... oncology, today announced that study designs and progress from ... a pivotal global Phase 3 clinical trial in relapsed/refractory ... clinical trial in small cell lung cancer, will be ... 2014 Congress being held September 26-30, in ...
(Date:9/19/2014)... Sept. 19, 2014 Harwood Feffer LLP ( ... of directors of PDL BioPharma, Inc. ("PDL" or the ... board has breached its fiduciary duties to shareholders or ... 16, 2014, the Company disclosed: "On September 11, 2014, ... firm, Ernst & Young LLP ("EY"), that it was ...
Breaking Medicine Technology:Cell Line Development Market Worth $3.96 Billion by 2019 2Cell Line Development Market Worth $3.96 Billion by 2019 3Cell Line Development Market Worth $3.96 Billion by 2019 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 2CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 3CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 4CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 5CytRx Announces Presentation of Aldoxorubicin Global Phase 3 Soft Tissue Sarcomas and Global Phase 2b Small Cell Lung Cancer Trial Designs at ESMO 2014 Congress 6Harwood Feffer LLP Announces Investigation of PDL BioPharma, Inc. 2
... Feb. 23, 2011 Plexus Biomedical Inc. has been ... and Drug Administration to market the first device clinically ... Hemorrhoids associated with vaginal delivery are a frequent complication ... women in the U.S. every year. The ...
... Inc. (Nasdaq: MAPP ) today announced that the ... Citi,s 2011 Global Healthcare Conference , Wednesday, March 2, at ... , Thursday, March 3, at 10:00 a.m. ET in ... March 9, at 10:15 a.m. ET in BostonBarclays Capital 2011 ...
Cached Medicine Technology:Plexus Biomedical Inc. Gains FDA Approval of the First Medical Device to Help Prevent External Hemorrhoids During Vaginal Childbirth 2
(Date:9/22/2014)... 2014 Don Allred Insurance is pleased to ... Burlington, NC. The satellite office, located in the Holly Hill ... 15, 2014, and offer all of the same professional services ... Allred Insurance spokesperson Scott Allred cites an expanding client base ... two of the major factors driving the decision to open ...
(Date:9/22/2014)... 22, 2014 Ethane Web Technologies, an ... to have announced affordable website redesign. The website redesign ... which are unsatisfied with their present websites and want ... to pay a big amount for this job. ... advanced tool, techniques, and experienced manpower so that it ...
(Date:9/22/2014)... Colorado's grand experiment with legal recreational marijuana for adults ... revenue for the state. , According to the ... was sold in Colorado dispensaries during the first five ... , But the success of these retail shops has ... the thousands of consumers now seeking out cannabis dispensaries ...
(Date:9/22/2014)... Available research evidence supports the use of deep ... who don,t respond to other treatments, concludes a review ... , official journal of the Congress of Neurological ... Lippincott Williams & Wilkins , a part of ... specific bilateral DBS techniques are recommended for treatment of ...
(Date:9/22/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... GLOBAL MARKETS, the global market for autoimmune disease ... billion by 2019, with a five-year compound annual ... holds the highest market potential due to an ... western lifestyles. , In recent decades, autoimmune ...
Breaking Medicine News(10 mins):Health News:Allred Insurance to Open New Burlington Branch Office 2Health News:Ethane Web Technologies Announces Affordable Website Redesign Service 2Health News:Colorado Cannabis Dispensary Creates a Unique In-Store Sales System, That Leaves the Old-School Retail Approach in the Dust 2Health News:Colorado Cannabis Dispensary Creates a Unique In-Store Sales System, That Leaves the Old-School Retail Approach in the Dust 3Health News:Evidence supports deep brain stimulation for obsessive-compulsive disorder 2Health News:Evidence supports deep brain stimulation for obsessive-compulsive disorder 3Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 2Health News:Global Market for Autoimmune Disease Diagnostics to Reach Nearly $13.1 Billion in 2019; Southern Asia Holds the Highest Potential 3
... known about anticancer benefits of supplements, researchers caution , SUNDAY, ... may do nothing to protect men against bladder cancer and ... , In one study examining vitamin use, researchers analyzed more ... part in prostate screenings. , More than 60 percent ...
... 30 (HealthDay News) -- A study in mice suggests that ... scientists say. , Women may begin taking part in the ... added. , "We believe that this vaccine will someday be ... same way that vaccines have prevented many childhood diseases," principal ...
... just how sticking needles into the body can ease pain. ... Nature Neuroscience, a team at the University of Rochester ... in parlaying some of the effects of acupuncture in the ... the beneficial effects of acupuncture in mice by adding a ...
... ... $125 or more by FedEx Ground service to the 48 contiguous states in acknowledgment of ... allergy products company in the country, with over 10,000 referring doctors and 22 years of ... ...
... ... , ... Insurance Services, LLC ( HCCMIS ), is now utilizing CMN for health-care provider network administration in ...   Larger worldwide network directory with 400,000+ doctors and 7,000+ ...
... shallow or unfamiliar waters, experts say , SATURDAY, May 29 ... 14 are hospitalized each year because of a diving injury, ... spinal cord injury, researchers say. , To encourage diver safety, ... near any body of water and to jump feet first ...
Cached Medicine News:Health News:Vitamins Fail to Protect Men Against Bladder Cancer 2Health News:Acupuncture's molecular effects pinned down 2Health News:National Allergy Supply Announces Free Ground Shipping For Its Customers 2Health News:HCC Medical Insurance Services Chooses CMN as Network Administrator 2Health News:Dive Safely -- Or Risk Spinal Cord Damage 2
... instruments have been designed to provide ... tool for situations requiring precise hemostasis. ... 25 gauge intraocular, bipolar, diathermy instruments. ... target tissues for fine-tip hemostasis or ...
... first steps any hospital or health system ... powerful, most effective tools available for physicians ... clinician documentation and electronic medical record (EMR) ... this goal. In fact, its the most ...
... specialty Eraser instruments have been designed ... the right tool for situations requiring ... series of 25 gauge intraocular, bipolar, ... treatment of target tissues for fine-tip ...
... ChartingPlus proves itself to over 2,000 medical ... with the user in mind, ChartingPlus relies ... and dynamic features to improve documentation quality ... Our medical content is specific ...
Medicine Products: